While Cytokinetics Inc has underperformed by -3.95%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CYTK fell by -52.45%, with highs and lows ranging from $75.71 to $34.19, whereas the simple moving average fell by -32.18% in the last 200 days.
On February 07, 2025, Citigroup started tracking Cytokinetics Inc (NASDAQ: CYTK) recommending Buy. A report published by Stifel on January 22, 2025, Initiated its previous ‘Buy’ rating for CYTK. RBC Capital Mkts also rated CYTK shares as ‘Outperform’, setting a target price of $80 on the company’s shares in an initiating report dated November 08, 2024. Goldman August 13, 2024d the rating to Neutral on August 13, 2024, and set its price target from $85 to $60. UBS January 24, 2024d its ‘Buy’ rating to ‘Neutral’ for CYTK, as published in its report on January 24, 2024. Morgan Stanley’s report from January 05, 2024 suggests a price prediction of $90 for CYTK shares, giving the stock a ‘Equal-Weight’ rating. Goldman also rated the stock as ‘Buy’.
Analysis of Cytokinetics Inc (CYTK)
Further, the quarter-over-quarter increase in sales is 912.38%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Cytokinetics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. Taking into account the quick ratio of the company, currently set at 6.17, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.80M can be a very valuable indicator of volatility for CYTK stock. On a monthly basis, the volatility of the stock is set at 6.43%, whereas on a weekly basis, it is put at 10.36%, with a loss of -7.81% over the past seven days. Furthermore, long-term investors anticipate a median target price of $78.95, showing growth from the present price of $34.57, which can serve as yet another indication of whether CYTK is worth investing in or should be passed over.
How Do You Analyze Cytokinetics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.60%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 109.77% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CYTK shares are owned by institutional investors to the tune of 109.77% at present.
